Cargando…

Comparison between talazoparib and conventional chemotherapy in the treatment of HER2-positive breast cancer patients: A retrospective study

BACKGROUND: The benefits of talazoparib compared with conventional chemotherapy in HER2-negative advanced breast cancer (ABC) remain unclear. METHODS: Patients older than 18 years, with a deleterious germline BRCA1/2 (gBRCA1/2) mutated, metastatic, or locally advanced and HER2-positive breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ning, Yu, Xiaopeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422399/ https://www.ncbi.nlm.nih.gov/pubmed/36045677 http://dx.doi.org/10.3389/fimmu.2022.901636

Ejemplares similares

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
por: Belz, Jodi E., et al.
Publicado: (2017)

Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
por: Liu, Xuan, et al.
Publicado: (2022)

RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
por: Li, Si, et al.
Publicado: (2018)

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2
por: Narváez, Dana, et al.
Publicado: (2022)

KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer
por: Muraro, Elena, et al.
Publicado: (2022)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
por: Wong, Fu Hou, et al.
Publicado: (2022)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
por: Li, Feifei, et al.
Publicado: (2022)

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
por: Batalha, Sofia, et al.
Publicado: (2023)

Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
por: Wang, Li, et al.
Publicado: (2022)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
por: Rugo, Hope S, et al.
Publicado: (2019)

Timely Genetic Testing and Therapy Management in Patients With gBRCA-Mutated Metastatic Breast Cancer Receiving Talazoparib
por: Martinez, Ashley, et al.
Publicado: (2022)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

A Phase I trial of talazoparib in patients with advanced hematologic malignancies
por: Gopal, Ajay K, et al.
Publicado: (2021)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Association between the systemic immune-inflammation index and the efficacy of neoadjuvant chemotherapy, prognosis in HER2 positive breast cancer—a retrospective cohort study
por: Gu, Qiang, et al.
Publicado: (2023)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
por: Tateishi, Kaho, et al.
Publicado: (2023)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Efficacy of Neoadjuvant Single or Dual Anti-HER-2 Therapy Combined with Chemotherapy in Patients with HER-2-Positive Breast Cancer: A Single-Center Retrospective Study
por: He, Qian, et al.
Publicado: (2021)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
por: Wang, Xinzhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_imdrb7p2lr0cn3fudtnoc32700